Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline.

Investing in stocks comes with the risk that the share price will fall. Anyone who held Immatics N.V. (NASDAQ:IMTX) over the last year knows what a loser feels like. To wit the share price is down 53% ...

Company to host conference call on Wednesday, March 17 at 8:30 am EST ·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation ·Tumor ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data ...

immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine Tuebingen, February 16, 2010 - immatics biotechnologies GmbH, a ...

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

- New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010 - IMA901 Phase II Trial has Shown the ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immatics (NASDAQ:IMTX) stands against other ...

Moderna Inc. agreed to pay German biotechnology company Immatics NV as much as $1.8 billion in a broad-ranging, multiyear collaboration on developing cancer therapies using messenger RNA and other ...